SCHEMBL25979704

SCHEMBL25979704

c1ccc(-c2nc(-c3ccccc3)nc(-c3ccc4c(c3)oc3cc(-c5ccc(N(c6ccccc6)c6ccc7oc8ccccc8c7c6)cc5)ccc34)n2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 1/20 0.38
MMP13 P45452 1/20 0.38
PLA2G2A P14555 2/20 0.38
PLA2G4A P47712 2/20 0.38
HCRTR1 O43613 1/20 0.37
ALDH1A1 P00352 5/20 0.36
KDM4E B2RXH2 4/20 0.36
HPGD P15428 4/20 0.36
MAPT P10636 3/20 0.36
AHR P35869 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
GAA P10253 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
POLB P06746 1/20 0.34
CHEK2 O96017 1/20 0.34
PDE5A O76074 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25979094 0.99 PLA2G2A (0.40) MMP12MMP13PLA2G2APLA2G4AHCRTR1
SCHEMBL25979410 0.99 MAPT (0.37) MMP12MMP13PLA2G2APLA2G4AHCRTR1
SCHEMBL26779174 0.98 PLA2G2A (0.38) MMP12MMP13PLA2G2APLA2G4AHCRTR1
SCHEMBL25978772 0.97 MAPT (0.38) MMP12MMP13PLA2G2APLA2G4AHCRTR1
SCHEMBL25979407 0.97 L3MBTL1 (0.37) MMP12MMP13PLA2G2APLA2G4AHCRTR1
SCHEMBL25979097 0.96 PLA2G2A (0.40) MMP12MMP13PLA2G2APLA2G4AHCRTR1
SCHEMBL25978774 0.96 MAPT (0.37) MMP12MMP13PLA2G2APLA2G4AHCRTR1
SCHEMBL24574979 0.96 ALDH1A1 (0.35) MMP12MMP13PLA2G2APLA2G4AALDH1A1
SCHEMBL25978749 0.96 ALDH1A1 (0.35) MMP12MMP13PLA2G2APLA2G4AALDH1A1
SCHEMBL25979291 0.96 ALDH1A1 (0.35) MMP12MMP13PLA2G2APLA2G4AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
EP-4227301-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT Materials Co., Ltd. (KR) 2023-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY1, CYP1A1, CYP1B1 MMP12 4355/4885MMP13 4837/4885PLA2G2A 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.